The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
An anti-human interleukin 5 receptor (hIL-5R) humanized immunoglobulin G1 (IgG1) and an anti-CD20 chimeric IgG1 produced by rat hybridoma YB2/0 cell lines showed more than 50-fold higher antibody-dependent cellular cytotoxicity (ADCC) using purified human peripheral blood mononuclear cells as effector than those produced by Chinese hamster ovary (CHO) cell lines. Monosaccharide composition and oligosaccharide profiling analysis showed that low fucose (Fuc) content of complex-type oligosaccharides was characteristic in YB2/0-produced IgG1s compared with high Fuc content of CHO-produced IgG1s. YB2/0-produced anti-hIL-5R IgG1 was subjected to Lens culinaris aggulutin affinity column and fractionated based on the contents of Fuc. The lower Fuc IgG1 had higher ADCC than the IgG1 before separation. In contrast, the content of bisecting GlcNAc of the IgG1 affected ADCC much less than that of Fuc. In addition, the correlation between Gal and ADCC was not observed. When the combined effect of Fuc and bisecting GlcNAc was examined in anti-CD20 IgG1, only a severalfold increase of ADCC was observed by the addition of GlcNAc to highly fucosylated IgG1. Quantitative PCR analysis indicated that YB2/0 cells had lower expression level of FUT8 mRNA, which codes alpha1,6-fucosyltransferase, than CHO cells. Overexpression of FUT8 mRNA in YB2/0 cells led to an increase of fucosylated oligosaccharides and decrease of ADCC of the IgG1. These results indicate that the lack of fucosylation of IgG1 has the most critical role in enhancement of ADCC, although several reports have suggested the importance of Gal or bisecting GlcNAc and provide important information to produce the effective therapeutic antibody.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is ideal as increases in fucosylation have been correlated with decreased ADCC activity and decreased FcγRIIIa and FcγRIIb binding affinity. 40 , 41 , 42 , 43”
From Dynamic pH profiles drive higher cell‐specific and volumetric productivity (2026) · cites this paper as [42]
In the citing paper
“lower cell specific productivity has been shown to allow for more mature glycoforms, including G2F. 42”
From Dynamic pH profiles drive higher cell‐specific and volumetric productivity (2026) · cites this paper as [42]
In the citing paper
“Enriching the abundance of mAb N-glycoforms with β1,4-linked galactose (Gal) can also be desirable as it has been shown to enhance complement-dependent cytotoxicity (CDC), another mechanism for the selective depletion of tumour cells by Fc activation of the complement pathway [16–21].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [16]
In the citing paper
“The addition of bisecting β1,4-linked N-acetylglucosamine (GlcNAc) by endogenous or recombinant N-acetylglucosaminyltransferase III (GnT-III in YB2/0 and CHO cells respectively) or via in vitro glycan remodelling has also been linked to increased ADCC in IgGs, albeit to a lesser extent than afucosylation [15–17].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [16]
In the citing paper
“It was reported that afucosylated Fc domain glycans of human IgG1 could enhance the binding to FcγRIIIa subtype receptors of natural killer cells (Shields et al., 2002;Shinkawa et al., 2003;Niwa et al., 2005;Iida et al., 2006;Subedi and Barb, 2016).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Shinkawa et al., 2003
Citations
Cites
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Deisenhofer, J. (1981) · PubMed · Cited by 1,422
Deisenhofer, J. (1981) · Biochemistry · doi:10.1021/bi00512a001 · Cited by 1,333
Parekh, R. B., Dwek, R. A., Sutton, B. J., Fernandes, D. L., Leung, A., Stanworth, D., Rademacher, T. W., Mizuochi, T., Taniguchi, T., Matsuta, K., et al. (1985) · Nature · doi:10.1038/316452a0 · Cited by 1,170
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
Lewis, G. D., Figari, I., Fendly, B., Lee Wong, W., Carter, P., Gorman, C., & Shepard, H. M. (1993) · Cancer Immunology, Immunotherapy · doi:10.1007/bf01518520 · Cited by 498
Refined Structure of an Intact IgG2a Monoclonal Antibody,
Harris, L. J., Larson, S. B., Hasel, K. W., & McPherson, A. (1997) · Biochemistry · doi:10.1021/bi962514+ · Cited by 451
Crystallographic structure of an intact IgG1 monoclonal antibody 1 1Edited by I. A. Wilson
Harris, L. J., Skaletsky, E., & McPherson, A. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1508 · Cited by 440
Research works printed but not linked: 2
- Rademacher, 1986, Biochem. Soc. Symp., 51, 131
- Kumpel, 1994, Hum. Antib. Hybrid., 5, 143
Cited by
Items 701–800 of 1,000
A general Fc engineering platform for the next generation of antibody therapeutics
Chen, D., Zhao, Y., Li, M., Shang, H., Li, N., Li, F., Wang, W., Wang, Y., Jin, R., Liu, S., et al. (2020) · Theranostics · doi:10.7150/thno.51299 · Cited by 26
“Glycoengineering or mutagenesis increases the affinity of Fc for FcγRIIIa on immune effector cells, leading to enhanced ADCC [2, 4-11].”
BackgroundAntibody mediated activation of natural killer cells in malaria exposed pregnant women
Damelang, T., Aitken, E. H., Hasang, W., López, E., Killian, M., Unger, H. W., Salanti, A., Shub, A., McCarthy, E. A., Kedzierska, K., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-83093-4 · Cited by 27
mAbs N-glycosylation: Implications for biotechnology and analytics
Wang, T., Liu, L., & Voglmeir, J. (2022) · Carbohydrate Research · doi:10.1016/j.carres.2022.108541 · Cited by 28
Bharadwaj, P., Shrestha, S., Pongrácz, T., Catalano, C., Sharma, S., Moine, A. L., de Haan, N., Murakami, N., Riella, L. V., Holovská, V., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100818 · Cited by 31
Synthesis of a N-glycan nonasaccharide of the bisecting type with additional core-fucose
Schuberth, R., & Unverzagt, C. (2005) · Tetrahedron Letters · doi:10.1016/j.tetlet.2005.04.061 · Cited by 26
Haryadi, R., Zhang, P., Chan, K. F., & Song, Z. (2012) · Bioengineered · doi:10.4161/bioe.22262 · Cited by 27
“7 The conformation of Tyr296 is more flexible for FcγRIIIa in afucosylated Fc than in fucosylated Fc.7 Tyr296 has already been indicated in the interaction with FcγRIIIa.2,8 Enhanced ADCC was not only observed for the afucosylated antibody in in vitro assays, it was also confirmed in vivo in patients or animal models.…”
BackgroundInfluentialRendić, D., Sharrow, M., Katoh, T., Overcarsh, B., Nguyen, K., Kapurch, J. R., Aoki, K., Wilson, I. B. H., & Tiemeyer, M. (2010) · Glycobiology · doi:10.1093/glycob/cwq119 · Cited by 27
“…of core α6-linked Fuc to N-linked glycans of immunoglobulins inversely correlates with the efficiency of antibody-dependent cellular cytotoxicity (Shinkawa et al. 2003), and Notch-based signaling requires the direct modification of the Notch polypeptide with O-linked Fuc residues (Okajima and…”
BackgroundModel-Driven Engineering of N-Linked Glycosylation in Chinese Hamster Ovary Cells
Stach, C. S., McCann, M. G., O’Brien, C. M., Le, T. S., Somia, N. V., Chen, X., Lee, K., Fu, H., Daoutidis, P., Zhao, L., et al. (2019) · ACS Synthetic Biology · doi:10.1021/acssynbio.9b00215 · Cited by 29
Nagashima, H., Tezuka, T., Tsuchida, W., Maeda, H., Kohroki, J., & Masuho, Y. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.02.003 · Cited by 27
Glycosylation pattern of humanized IgG-like bispecific antibody produced by recombinant CHO cells
Kim, W.-D., Tokunaga, M., Ozaki, H., Ishibashi, T., Honda, K., Kajiura, H., Fujiyama, K., Asano, R., Kumagai, I., Ōmasa, T., et al. (2009) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-009-2152-z · Cited by 26
“The absence of fucose or the presence of a bisecting N-acetylglucosamine (GlcNAc) of Fc glycans has significantly increased binding to FcγR and has consequently shown enhanced ADCC ( Shinkawa et al. 2003 ).”
BackgroundKoga, Y., Aoki‐Saito, H., Kamide, Y., Sato, M., Tsurumaki, H., Yatomi, M., Ishizuka, T., & Hisada, T. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.865318 · Cited by 26
Adult T-cell leukemia–lymphoma
Tsukasaki, K. (2012) · Hematology · doi:10.1179/102453312x13336169155330 · Cited by 25
Liang, W., Mao, S., Li, M., Zhang, N., Sun, S., Fang, H., Zhang, J., Gu, J., Wang, J., & Li, W. (2019) · Molecular Immunology · doi:10.1016/j.molimm.2019.06.011 · Cited by 25
Lewis, D. J., & Rook, A. H. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1760096 · Cited by 25
“FcγR binding increases the activity of the cytotoxic cells and induces the release of granzyme, perforin, and tumor necrosis factor, causing lysis of the antibody-targeted cell [14,15].”
BackgroundMaeda, T., & Nishimura, S. (2007) · Chemistry - A European Journal · doi:10.1002/chem.200700760 · Cited by 25
Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs
Mimoto, F., Kadono, S., Katada, H., Igawa, T., Kamikawa, T., & Hattori, K. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.11.017 · Cited by 26
Site-specific N-glycosylation analysis of soluble Fcγ receptor IIIb in human serum
Yagi, H., Takakura, D., Roumenina, L. T., Fridman, W. H., Sautès‐Fridman, C., Kawasaki, N., & Kato, K. (2018) · Scientific Reports · doi:10.1038/s41598-018-21145-y · Cited by 26
Impact of IgG1 N-glycosylation on their interaction with Fc gamma receptors
Cambay, F., Raymond, C., Brochu, D., Gilbert, M., Tu, T.-M., Cantin, C., Lenferink, A. E. G., Grail, M., Henry, O., Crescenzo, G. D., et al. (2020) · Current Research in Immunology · doi:10.1016/j.crimmu.2020.06.001 · Cited by 26
Global Impact of Monoclonal Antibodies (mAbs) in Children: A Focus on Anti-GD2
Larrosa, C., Mora, J., & Cheung, N. V. (2023) · Cancers · doi:10.3390/cancers15143729 · Cited by 25
Integrin receptors on tumor cells facilitate NK cell‐mediated antibody‐dependent cytotoxicity
Anikeeva, N., Steblyanko, M. A., Fayngerts, S., Kopylova, N., Marshall, D. J., Powers, G. D., Sato, T., Campbell, K. S., & Sykulev, Y. K. (2014) · European Journal of Immunology · doi:10.1002/eji.201344179 · Cited by 25
Establishment of a novel lectin–antibody ELISA system to determine core-fucosylated haptoglobin
Shimomura, M., Nakayama, K., Azuma, K., Terao, N., Nishino, K., Takamatsu, S., Nakano, M., Takahashi, S., Kobayashi, Y., Murata, K., et al. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.03.037 · Cited by 24
From the γ-Glutamyl Cycle to the Glycan Cycle: A Road with Many Turns and Pleasant Surprises
Taniguchi, N. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.x109.023150 · Cited by 24
Donor Assists Acceptor Binding and Catalysis of Human α1,6-Fucosyltransferase
Kötzler, M. P., Blank, S., Bantleon, F. I., Wienke, M., Spillner, E., & Meyer, B. (2013) · ACS Chemical Biology · doi:10.1021/cb400140u · Cited by 25
Quilizumab is an Afucosylated Humanized Anti-M1 Prime Therapeutic Antibody
Brightbill, H. D., Lin, Y. L., Lin, Z., Tan, M., Meng, Y., Balázs, M., Chung, S., & Wu, L. C. (2013) · Clinical Anti-Inflammatory & Anti-Allergy Drugs · doi:10.2174/22127038114019990003 · Cited by 28
Zheng, C., Zhuang, C., Chen, Y., Fu, Q., Qian, H., Wang, Y., Qin, J., Wu, X. X., & Qi, N. (2017) · Process Biochemistry · doi:10.1016/j.procbio.2017.11.013 · Cited by 29
Iwamoto, M., Sekiguchi, Y., Nakamura, K., Kawaguchi, Y., Honda, T., & Hasegawa, J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193534 · Cited by 26
Self-citationKamiya, Y., Satoh, T., & Kato, K. (2014) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2014.03.008 · Cited by 25
“For example, defucosylation of Fc glycans dramatically enhances their antibody-dependent cellular cytotoxicity by increasing their affinity for the Fcg receptor III (FcgRIII) [23,24].”
BackgroundSeino, J., Fujihira, H., Nakakita, S.-I., Masahara-Negishi, Y., Miyoshi, E., Hirabayashi, J., & Suzuki, T. (2016) · Glycobiology · doi:10.1093/glycob/cww048 · Cited by 23
Ishiguro, T., Kawai, S., Habu, K., Sugimoto, M., Shiraiwa, H., Iijima, S., Ozaki, S., Matsumoto, T., & Yamada‐Okabe, H. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01663.x · Cited by 25
Wang, J., Huang, C., Zhou, J., Zhao, K., & Li, Y. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104282 · Cited by 24
Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies
Mata, J. J., Rebollo-Liceaga, J., Martinez-Navarro, E., Manzano, R. G., Brugarolas, A., Juan, M., & Sureda, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.926289 · Cited by 28
Natural killer cells: the next wave in cancer immunotherapy
Chen, X., Jiang, L., & Liu, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.954804 · Cited by 33
Zhang, T., Zhang, M., Yang, L., Gao, L., & Sun, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1032355 · Cited by 24
“Firstly, CF occurs typically in human immunoglobulin G (IgGs) and plays a significant role in IgG function.”
BackgroundParsons, T. B., Patel, M. K., Boraston, A. B., Vocadlo, D. J., & Fairbanks, A. J. (2010) · Organic & Biomolecular Chemistry · doi:10.1039/b926078a · Cited by 23
Strategies for Engineering Protein N-Glycosylation Pathways in Mammalian Cells
Wang, Q., Stuczynski, M. C., Gao, Y., & Betenbaugh, M. J. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2760-9_20 · Cited by 31
Leveraging a CHO cell line toolkit to accelerate biotherapeutics into the clinic
Wright, C. M., Alves, C. S., Kshirsagar, R., Pieracci, J. P., & Estes, S. D. (2017) · Biotechnology Progress · doi:10.1002/btpr.2548 · Cited by 25
Schwedler, C., Häupl, T., Kalus, U. J., Blanchard, V., Burmester, G. R., Poddubnyy, D., & Hoppe, B. (2018) · Arthritis Research & Therapy · doi:10.1186/s13075-018-1540-0 · Cited by 27
Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG
Alderson, K. L., Luangrath, M. A., Elsenheimer, M. M., Gillies, S. D., Navid, F., Rakhmilevich, A. L., & Sondel, P. M. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1372-8 · Cited by 23
“Monoclonal antibodies with such altered side chains on the Fc portion are more potent inducers of ADCC [5, 6].”
Enhancing Fc ‐mediated effector functions of monoclonal antibodies: The example of HexaBodies
van der Horst, H. J., & Mutis, T. (2024) · Immunological Reviews · doi:10.1111/imr.13394 · Cited by 26
Maki, Y., Matsui, Y., Hayakawa, T., Yamamoto, S., Kinoshita, M., & Suzuki, S. (2017) · Journal of Chromatography A · doi:10.1016/j.chroma.2017.03.019 · Cited by 22
Yamaguchi, Y., Wakaizumi, N., Irisa, M., Maruno, T., Shimada, M., Shintani, K., Nishiumi, H., Yogo, R., Yanaka, S., Higo, D., et al. (2022) · mAbs · doi:10.1080/19420862.2022.2038531 · Cited by 22
Shapiro, M. A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1379738 · Cited by 24
The Role of Glycosylation in Therapeutic Antibodies
Spearman, M. A., Dionne, B., & Butler, M. (2011) · Cell engineering · doi:10.1007/978-94-007-1257-7_12 · Cited by 30
Obstacles to ideal anti-HIV antibody-dependent cellular cytotoxicity responses
Wren, L. H., Stratov, I., Kent, S. J., & Parsons, M. S. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.08.035 · Cited by 25
“1, Abs best uited to mediate ADCC: (1) are specific for antigens present on the urface of putative target cells; (2) carry the constant region of the gG1 or IgG3 subclass [30,31]; (3) lack either sialic acid or fucose glyans [46–48].”
BackgroundSchwedler, C., Kaup, M., Petzold, D., Hoppe, B., Braicu, E. I., Sehouli, J., Ehlers, M., Berger, M., Tauber, R., & Blanchard, V. (2014) · Electrophoresis · doi:10.1002/elps.201300414 · Cited by 23
Arabinosylation of recombinant human immunoglobulin-based protein therapeutics
Hossler, P., Chumsae, C., Racicot, C., Ouellette, D., Ibraghimov, A. R., Serna, D., Mora, A., McDermott, S., Labkovsky, B., Scesney, S. M., et al. (2017) · mAbs · doi:10.1080/19420862.2017.1294295 · Cited by 27
“Thus, changing the protein glycosylation profile of recombinant protein therapeutics, especially fucose levels, is anticipated to affect the resulting ADCC activity, as has been reported in the literature.(9,10) Purified mAb-1 was evaluated via Biacore for FcgR binding, and the results are shown in Table 6.”
BackgroundMethodDrug discovery and therapeutic delivery for the treatment of B and T cell tumors
Stephenson, R. E., & Singh, A. K. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.010 · Cited by 25
Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy
Koch, J., & Tesar, M. (2017) · Transfusion Medicine and Hemotherapy · doi:10.1159/000479981 · Cited by 23
Comprehensive manipulation of glycosylation profiles across development scales
Loebrich, S., Clark, E. C., Ladd, K., Takahashi, S., Brousseau, A., Kitchener, S., Herbst, R., & Ryll, T. (2018) · mAbs · doi:10.1080/19420862.2018.1527665 · Cited by 24
Muenchhoff, M., Chung, A. W., Roider, J., Dugast, A., Richardson, S. I., Kløverpris, H. N., Leslie, A. J., Ndung’u, T., Moore, P. L., Alter, G., et al. (2020) · mSphere · doi:10.1128/msphere.00880-20 · Cited by 27
“Afucosylation directly increases ADCC activity by enhancing binding to Fc gamma receptor IIIa and is therefore used to enhance the therapeutic effects of monoclonal antibodies (49).”
Montesino, R., Calvo, L., Vallin, A., Rudd, P. M., Harvey, D. J., & Cremata, J. A. (2012) · Biologicals · doi:10.1016/j.biologicals.2012.04.005 · Cited by 22
Therapeutic cleavage of IgG: new avenues for treating inflammation
Nandakumar, K. S., & Holmdahl, R. (2008) · Trends in Immunology · doi:10.1016/j.it.2008.01.007 · Cited by 22
Antibody‐dependent Cellular Cytotoxicity ( ADCC )
Teillaud, J. (2012) · Wiley eBooks · doi:10.1002/9780470015902.a0000498.pub2 · Cited by 29
Uçaktürk, E. (2011) · Journal of Separation Science · doi:10.1002/jssc.201100684 · Cited by 22
The therapeutic potential of sialylated Fc domains of human IgG
Pleass, R. J. (2021) · mAbs · doi:10.1080/19420862.2021.1953220 · Cited by 25
Meng, X., Song, M., Vilaj, M. Ć., Štambuk, J., Mamatyusupu, D., Zhang, J., Liu, D., Wang, H., Zhang, X., Zhang, J., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11070614 · Cited by 26
“The addition of sialic acid to IgG can decrease its affinity for FcγRIII, thereby reducing the degree of ADCC, converting its function from pro- to anti-inflammatory [47].”
BackgroundInfluentialMrázek, H., Weignerová, L., Bojarová, P., Novák, P., Vaněk, O., & Bezouška, K. (2012) · Biotechnology Advances · doi:10.1016/j.biotechadv.2012.03.008 · Cited by 25
“However, non-fucosylated glycan structures of the Fc domain lead to enhanced binding to the FcγRIIIa receptor responsible for antibody-dependent-cell-mediated cytotoxicity (ADCC; Shields et al., 2002; Shinkawa et al., 2003).”
BackgroundLiu, C., Dong, S., Xu, X., Yin, Y., Shriver, Z. H., Capila, I., Myette, J. R., & Venkataraman, G. (2010) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2010.07.044 · Cited by 21
Fairbanks, A. J. (2010) · Comptes Rendus Chimie · doi:10.1016/j.crci.2010.05.014 · Cited by 21
Lappano, R., & Maggiolini, M. (2017) · Drugs · doi:10.1007/s40265-017-0738-9 · Cited by 26
“Mogamulizumab, which is characterized by a defucosylated Fc region that enhances antibody-dependent cytotoxicity [96], exhibited potent anticancer activity in relapsed patients with ATL and peripheral T-cell lymphoma with an acceptable toxicity profile [97, 98].”
BackgroundFonseca, M. H. G., Furtado, G. P., Bezerra, M. R. L., Pontes, L. Q., & Fernandes, C. F. C. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.07.141 · Cited by 24
Glyco-Engineering of Plant-Based Expression Systems
Fischer, R., Holland, T., Sack, M., Schillberg, S., Stöger, E., Twyman, R. M., & Buyel, J. F. (2018) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2018_76 · Cited by 27
A Single Route to Mammalian N‐Glycans Substituted with Core Fucose and Bisecting GlcNAc
Luber, T., Niemietz, M., Karagiannis, T., Mönnich, M., Ott, D., Perkams, L., Walcher, J., Berger, L., Pischl, M., Weishaupt, M., et al. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201807742 · Cited by 21
Structure and Dynamics of Immunoglobulin G Glycoproteins
Yagi, H., Yanaka, S., & Kato, K. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-2158-0_11 · Cited by 25
Seki, H., Huang, Y., Arakawa, T., Yamada, C., Kinoshita, T., Iwamoto, S., Higuchi, Y., Takegawa, K., & Fushinobu, S. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.010842 · Cited by 21
“The -1,6-fucosylation plays important roles in the functionalities of epidermal growth factor receptors, cell adhesion molecules (5), and antibody-dependent cellular toxicity (6), and altered core fucosylation levels have been observed in certain types of diseases (7–9).”
BackgroundOKUDA, T., Shimizu, K., Hasaba, S., & Date, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-55088-9 · Cited by 22
Serum immunoglobulin G N-glycome: a potential biomarker in endometrial cancer
Lin, S., Wang, Y., Wang, X., Yan, B., Lou, W., & Di, W. J. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-3504 · Cited by 23
Disruption of α‐mannosidase processing induces non‐canonical hybrid‐type glycosylation
Crispin, M., Aricescu, A. R., Chang, V. T.-C., Jones, E. Y., Stuart, D. I., Dwek, R. A., Davis, S. J., & Harvey, D. J. (2007) · FEBS Letters · doi:10.1016/j.febslet.2007.04.020 · Cited by 24
“The absence of core a1-6 fucosylation can significantly enhance ADCC effector function of antibodies [19].”
BackgroundPreparation of recombinant proteins in milk to improve human and animal health
Soler, É., Thépot, D., Rival‐Gervier, S., Jolivet, G., & Houdebine, L. (2006) · annales de biologie animale biochimie biophysique · doi:10.1051/rnd:2006029 · Cited by 21
Manabe, Y., Kasahara, S., Takakura, Y., Yang, X., Takamatsu, S., Kamada, Y., Miyoshi, E., Yoshidome, D., & Fukase, K. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.02.036 · Cited by 22
Recombinant Proteins and Monoclonal Antibodies
Jefferis, R. (2017) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2017_32 · Cited by 25
Modular Synthesis of Core Fucosylated N‐Glycans
Ott, D., Seifert, J., Prahl, I., Niemietz, M., Hoffman, J., Guder, J., Mönnich, M., & Unverzagt, C. (2012) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201200468 · Cited by 23
Quantitative assessment of mAb Fc glycosylation of CQA importance by capillary electrophoresis
Szigeti, M., Chapman, J., Borza, B., & Guttman, A. (2018) · Electrophoresis · doi:10.1002/elps.201800076 · Cited by 19
Wang, Q., Wang, T., Zhang, R., Yang, S., McFarland, K. S., Chung, C., Jia, H., Wang, L., Cipollo, J. F., & Betenbaugh, M. J. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27953 · Cited by 22
“For example, the removal of core fucose residues (α‐1,6 fucose) of multiple therapeutic antibodies increases their binding affinities to FcγRIII, therefore significantly enhancing their ADCC activity (Ferrara et al., 2006; Shields et al., 2002; Shinkawa et al., 2003).”
BackgroundFunctional and structural modifications of influenza antibodies during pregnancy
Jennewein, M. F., Košíková, M., Noelette, F. J., Radvák, P., Boudreau, C. M., Campbell, J. D., Chen, W. H., Xie, H., Alter, G., & Pasetti, M. F. (2022) · iScience · doi:10.1016/j.isci.2022.104088 · Cited by 21
B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma
Hagelstein, I., Engel, M., Hinterleitner, C., Manz, T., Märklin, M., Jung, G., Salih, H. R., & Zekri, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1002898 · Cited by 20
Systematic analysis of Fc mutations designed to enhance binding to Fc-gamma receptors
Hale, G., Davy, A. D., & Wilkinson, I. (2024) · mAbs · doi:10.1080/19420862.2024.2406539 · Cited by 22
The antibody paradigm: present and future development as a scaffold for biopharmaceutical drugs
Jefferis, R. (2009) · Biotechnology and Genetic Engineering Reviews · doi:10.5661/bger-26-1 · Cited by 22
Molecular engineering to improve antibodies’ anti-lymphoma activity
Peipp, M., van de Winkel, J. G. J., & Valerius, T. (2011) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2011.03.004 · Cited by 20
Kubota, T., Matsushita, T., Niwa, R., Kumagai, I., & Nakamura, K. (2010) · PubMed · Cited by 24
Self-citationSpecific increase in serum core-fucosylated haptoglobin in patients with chronic pancreatitis
Ueda, M., Kamada, Y., Takamatsu, S., Shimomura, M., Maekawa, T., Sobajima, T., Fujii, H., Nakayama, K., Nishino, K., Yamada, M., et al. (2016) · Pancreatology · doi:10.1016/j.pan.2016.01.004 · Cited by 20
Hagelkrüys, A., Wirnsberger, G., Stadlmann, J., Wöhner, M., Horrer, M., Vilagos, B., Jonsson, G., Kögler, M., Tortola, L., Novatchkova, M., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20200559 · Cited by 22
Taniguchi, N., Gu, J., Takahashi, M., & Miyoshi, E. (2004) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.80.82 · Cited by 21
Generation of a Mutant Mucor hiemalis Endoglycosidase That Acts on Core-fucosylated N-Glycans
Katoh, T., Katayama, T., Tomabechi, Y., Nishikawa, Y., Kumada, J., Matsuzaki, Y., & Yamamoto, K. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.737395 · Cited by 27
“Notably, IgG1 with the fucose-deficient N-glycan of Asn-297 in its Fc region shows increased binding affinity for the Fc receptor III on the effector cells, resulting in highly enhanced antibody-dependent cellular cytotoxicity (38, 39).”
BackgroundHatfield, G., Tepliakova, L., Gingras, G., Stalker, A., Li, X., Aubin, Y., & Tam, R. Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.972168 · Cited by 23
“Rather, our results provide further corroborating evidence with more recent studies that galactosylation further increases ADCC via FcgRIIIA binding (12, 21, 49) and is in contrast to previous studies that showed galactosylation had no effect (11, 13, 50).”
ResultComputational tools for predicting and controlling the glycosylation of biopharmaceuticals
Kontoravdi, C., & Jimenez del Val, I. (2018) · Current Opinion in Chemical Engineering · doi:10.1016/j.coche.2018.08.007 · Cited by 18
C-terminal lysine clipping of IgG1: impact on binding to human FcγRIIIa and neonatal Fc receptors
Faid, V., Leblanc, Y., Berger, M., Seifert, A., Bihoreau, N., & Chevreux, G. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.105730 · Cited by 20
Engineered Bifunctional Proteins for Targeted Cancer Therapy: Prospects and Challenges
Du, Y., & Xu, J. (2021) · Advanced Materials · doi:10.1002/adma.202103114 · Cited by 20
Chen, J., Fries, C. N., Berendam, S. J., Rodgers, N. S., Roe, E. F., Wu, Y., Li, S. H., Jain, R., Watts, B. E., Eudailey, J., et al. (2022) · Science Advances · doi:10.1126/sciadv.abq0273 · Cited by 23
A Clinical Viewpoint on the Use of Targeted Therapy in Advanced Gastric Cancer
Skórzewska, M., Gęca, K., & Polkowski, W. P. (2023) · Cancers · doi:10.3390/cancers15225490 · Cited by 21
“Approximately 30% of non-HER2-positive GC [186,187] display FGFR2b overexpression.”
BackgroundAntitumor Efficacy of Anti-GD2 IgG1 Is Enhanced by Fc Glyco-Engineering
Xu, H., Guo, H.-F., Cheung, I. Y., & Cheung, N. V. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0221 · Cited by 20
“An alternative approach to enhancing FcgR affinity is by modifying Fc glycosylation (14).”
BackgroundTechnical and Ethical Limitations in Making Human Monoclonal Antibodies (An Overview)
Glassy, M. C., & Gupta, R. K. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-586-6_2 · Cited by 23
Li, X., Guan, F., Li, D., Tan, Z., Yang, G., Wu, Y., & Huang, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.13539 · Cited by 19
“Depletion of core-fucose in human IgG1 enhances antibody-dependent cell-mediated cytotoxicity during cancer therapy [33].”
Bioprocess development of a stable FUT8−/−-CHO cell line to produce defucosylated anti-HER2 antibody
Yuan, Y., Zong, H., Bai, J., Han, L., Wang, L., Zhang, X., Zhang, X., Zhang, J., Xu, C., Zhu, J., et al. (2019) · Bioprocess and Biosystems Engineering · doi:10.1007/s00449-019-02124-7 · Cited by 20
Ohyama, Y., Nakajima, K., Renfrow, M. B., Novák, J., & Takahashi, K. (2020) · Expert Review of Proteomics · doi:10.1080/14789450.2020.1769479 · Cited by 23
“binding of the IgG Fc portion to FcγRIIIa on the natural killer cells [185].”
BackgroundZhang, Q., Joubert, M. K., Polozova, A., Guzman, R. D., Lakamsani, K., Kinderman, F. S., Xiang, D., Shami, A. S. E., Miscalichi, N., Flynn, G. C., et al. (2020) · Biotechnology Progress · doi:10.1002/btpr.3045 · Cited by 21
Differential Labeling of Glycoproteins with Alkynyl Fucose Analogs
Ma, C., Takeuchi, H., Hao, H., Yonekawa, C., Nakajima, K., Nagae, M., Okajima, T., Haltiwanger, R. S., & Kizuka, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176007 · Cited by 20
“In addition, the removal of core Fuc from therapeutic IgGs dramatically raises their antibody-dependent cellular cytotoxicity (ADCC) activity by ~100 fold [16,17], indicating that modulating core Fuc has important therapeutic value.”
BackgroundMatsushita, T. (2011) · The Korean Journal of Hematology · doi:10.5045/kjh.2011.46.3.148 · Cited by 21
Synthetic antibodies as therapeutics
Fuh, G. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.1.73 · Cited by 21
“, reduction of fucosylation) to improve the Fc effector function [96-100].”
BackgroundMonoclonal antibody-based therapeutics for leukemia
Li, Y., & Zhu, Z. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.3.319 · Cited by 20
“Alternatively, modifications of the glycosylation of the Fc domain by either addition of bisecting N-acetylglucosamine or deletion of fucose on N-linked oligosaccharide chain have also been shown to enhance the binding affinity between the Fc domain and its FcγR [82,83].”
BackgroundInfluential
Metadata
- Authors
- Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., Hanai, N., & Shitara, K.
- Affiliations
- Kyowa Kirin (Japan) (JP)
- Corresponding author
- Shitara, Kenya
- ORCID
- Uchida, Kazuhisa
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-01
- Volume
- 278
- Issue
- 5
- Pages
- 3466-3473
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2084136419
- Cited by
- 1,413
- References
- 33
- Citations by year
- 2026: 37 · 2025: 47 · 2024: 55 · 2023: 45 · 2022: 77 · 2021: 78 · 2020: 87 · 2019: 70 · 2018: 83 · 2017: 77 · 2016: 71 · 2015: 72 · 2014: 78 · 2013: 56 · 2012: 67
- FWCI
- 14.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6498 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- antibody-dependent cellular cytotoxicity, fucosylation, bisecting N-acetylglucosamine, galactose, FUT8, alpha-1,6-fucosyltransferase, humanized monoclonal antibody, CHO cell expression, antibody glycosylation, therapeutic antibodies
- MeSH terms
- Acetylglucosamine, Animals, Antibody-Dependent Cell Cytotoxicity, Base Sequence, Carbohydrate Conformation, Carbohydrate Sequence, Cell Line, Chromatography, Affinity, Fucose, Galactose, Cricetinae, Humans, Immunoglobulin G, Molecular Sequence Data, Oligosaccharides, Recombinant Fusion Proteins, Transfection, Polymerase Chain Reaction, CHO Cells, DNA Primers, Lectins, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.